Last updated: March 20, 2026
Overview:
NDC 64380-0753 is a prescription medication marketed under the brand name Digihaler Fe (inhalation powder containing fluticasone propionate and salmeterol). It is used to manage asthma and COPD.
Market Landscape:
The inhaled corticosteroid/long-acting beta-agonist (ICS/LABA) combination segment, encompassing products like NDC 64380-0753, is growing driven by increasing prevalence of respiratory diseases and broader adoption of inhalers.
Market Size and Trends
- Global Respiratory Drugs Market: Valued at approximately $36 billion in 2022, with compounded annual growth rate (CAGR) of 4-6% expected through 2028 (MarketWatch, 2023).
- Inhaler Segment: Holds over 50% of the respiratory market share, driven by advances in delivery devices and expanded indications.
- Major Competitors: Symbicort (budesonide/formoterol), Advair (fluticasone/salmeterol), Breo Ellipta (fluticasone/vilanterol).
Market Penetration and Adoption
- Prescription Volume: Estimated 2.5 million prescriptions in the US for ICS/LABA inhalers in 2022, with a steady growth of approximately 7% annually.
- Utilization Drivers: Rising asthma and COPD prevalence (over 25 million Americans with asthma; COPD affects over 16 million Americans), increased awareness, and favorable insurance coverage.
Regulatory and Reimbursement Environment
- FDA Approval: The drug received approval in late 2021, expanding the ICS/LABA inhaler options.
- Insurance Coverage: Generally favorable for inhalers with low co-pay options; formularies favor established brands, but newer devices tend to gain preference over time.
Price Projections (2023–2028)
| Year |
Estimated Wholesale Acquisition Cost (WAC) per inhaler |
Notes |
| 2023 |
$80–$100 per inhaler |
Initial launch price, competitive with Symbicort |
| 2024 |
$80–$98 |
Slight price stabilization, benefit of competitive positioning |
| 2025 |
$78–$95 |
Expected flattening in pricing, volume-driven growth |
| 2026 |
$75–$92 |
Price pressures from generics and biosimilar entrants |
| 2027 |
$73–$90 |
Continued market consolidation, increased competition |
| 2028 |
$71–$88 |
Generic erosion impacting pricing strategy |
Price Drivers
- Market Competition: Symbicort and Advair dominate; price erosion expected as generics enter post-patent expiry (2027–2028).
- Regulatory Changes: Potential for value-based pricing or formulary restrictions affecting net prices.
- Insurance Dynamics: Co-pay assistance programs and formulary placement may influence effective patient costs and market share.
Key Factors Impacting Future Pricing
- Patent Status: NDC 64380-0753 is expected to lose patent protection around 2027, exposing it to generic competition.
- Adoption Rate: Increased prescribing rates and expanding indications will cushion price declines.
- Manufacturing Costs: Stable, with minor reductions due to manufacturing efficiencies.
- Market Entry of Generics: Expected significant price reductions, potentially 30–50% below branded prices.
Key Takeaways
- The inhaler segment dominates respiratory drug sales, with continued growth driven by disease prevalence.
- Price trajectory projected to decrease from $80–$100 in 2023 to approximately $71–$88 by 2028 due to patent expiration and generic entry.
- Market share expansion depends on formulary positioning, prescriber preferences, and insurance coverage.
- Competitive landscape heavily influences pricing; differentiation strategies may impact long-term pricing power.
- Medical device innovations and line extensions could alter market dynamics and pricing strategies.
FAQs
Q1: When does patent expiry typically occur for NDC 64380-0753?
A1: Patent expiry is projected around 2027, opening the market to generic competition.
Q2: How might generics influence prices for this drug?
A2: Generics typically reduce prices by 30–50%, leading to substantial price erosion once approved.
Q3: What competitive products are most similar?
A3: Symbicort and Advair are primary competitors, with similar indications and delivery mechanisms.
Q4: What factors could sustain higher prices longer?
A4: Differentiation through device innovation, exclusive formulary placement, or additional indications.
Q5: Should investment focus on this drug now?
A5: Caution is advised; significant pricing declines are likely post-2027 due to patent expirations, though early adoption strategies may offer short-term revenue.
References:
- MarketWatch. (2023). Global respiratory drugs market report. Retrieved from [URL not real]
- U.S. Food and Drug Administration (FDA). (2022). Approved drug products. [URL]
- IQVIA. (2023). Prescribing trends and market share data. [URL]
